When it comes to pre-revenue biotechs, it's often a struggle to build an investment thesis beyond "if the medicine works, the ...
The company's latest presentation supports the idea that its lead program will make billions.
AstraZeneca’s new obesity pill, licensed from China’s Eccogene last year, has shown initial promise in early-stage trials.
Madrigal’s Rezdiffra has launched a new MASH market, but ‘tremendous change’ is on the horizon
With the FDA approval of the first specific drug for Metabolic Associated Steatohepatitis (MASH) in March this year, Madrigal’s Rezdiffra is a pioneer in a market set for rapid change. | With the FDA ...
While expected and seen as largely incremental, Jefferies analyst Peter Welford in a Tuesday note to investors said the detailed data for three early-stage assets support moving them into Phase IIb ...
Shares of Viking Therapeutics (NASDAQ: VKTX) fell on Monday, Nov. 4, despite some encouraging new data. Over the weekend, the ...
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock ...
Viking Therapeutics’ GLP-1 pill candidate for treating obesity showed promise in its latest trial results, the clinical-stage ...
Viking Therapeutics shares climbed 9% on Monday after the drug developer's oral obesity treatment helped reduce body weight ...
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Viking Therapeutics (VKTX – Research ...
Viking Therapeutics shares rose Monday morning before reversing course and declining after reporting the latest results from ...
Viking Therapeutics Inc. cheered analysts Monday after the biotech posted data on its oral weight-loss drug showing better-than-expected results from a Phase 1 trial. The news sent the stock sharply ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback